Table 1. Comparison of clinical characteristics (S1 Appendix).
| Demographics | Average Number of Participants with OSA (on CPAP) or at risk for OSA (STOP-Bang ≥ 3) | Control (Daily Opioid Use with OSA) | P-value | Average Number of Participants Not Likely to Have OSA (STOP-Bang < 3) or Neg- Polysomnography | Pre-Post P-value |
|---|---|---|---|---|---|
| Age | 60.5 +/- 11.6 | 57.2 +/- 10.1 | 0.074 | 61.5 +/- 15.4 | 0.48 |
| BMI *** | 31.8 +/- 6.8 | 35.1 +/- 6.8 | <0.0001 | 28.7 +/- 6.3 | 0.0017 |
| Morphine Equivalent mg/d at Conclusion of Study ≥ 12 months | 33.7 +/- 23.5 | 33.8 +/- 25.5 | 0.98 | 34.0 +/- 23.5 | 0.94 |
| Demographics | Average Percentage of Participants with OSA (on CPAP) or at risk for OSA (STOP-Bang > 3) | Control (Daily Opioid Use with OSA) | P-value | Average Percentage of Participants Not Likely to Have OSA (STOP-Bang < 3) or Neg- Polysomnography | Pre-Post P-Value |
| Race (Caucasian) | 98% | 92% | 0.1 | 100% | 0.27 |
| Gender (Male)** | 50% | 94% | <0.0001 | 18% | <0.0001 |
| Diabetes*** | 40% | 35% | 0.53 | 11% | 0.0009 |
| Cardiovascular Disease** | 27% | 18% | 0.19 | 11% | 0.020 |
| Hypertension* | 86% | 79% | 0.16 | 56% | 0.0014 |
| Gastroesophageal Reflux Disease | 15% | N/A | N/A | 11% | 0.089 |
| Thyroid Disease (All Forms) | 29% | N/A | N/A | 27% | 0.83 |
| Pulmonary Disease (All Varieties) | 27% | N/A | N/A | 23% | 0.66 |
| Active Cancer | 9.6% | N/A | N/A | 9.8% | 0.69 |
| Chronic Kidney Disease | 15% | N/A | N/A | 11% | 0.57 |
| Concurrent Benzodiazepine Use | 60% | N/A | N/A | 70% | 0.31 |
| Concurrent Pregabalin Use | 29% | N/A | N/A | 28% | 0.87 |
* = p value of < 0.01
** = p value of < 0.05
*** = p value of < 0.001